Project Grant R44EY038138
Award Date 9/15/25
Completion Date 8/31/27
Dollars Obligated $1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Syracuse, NY 13210, USA
Similar Awards
- The National Eye Institute (NEI), under the U.S. Department of Health and Human Services, awarded a $321,904 Project Grant to Proteris Biotech, Inc. through the Vision Research federal grant program (CFDA 93.867). The award, spanning August 1, 2025 to July 31, 2026, will fund the early development of the natural tear protein clusterin (CLU) as a novel approach to treat dry eye disease. The research aims to conduct non-GMP stability analysis of the drug substance and product, as well as perform...
- This federal Project Grant award of $234,000.00 from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), supports research to enhance stem cell restoration of intraocular pressure (IOP) homeostasis through senolytic treatments. The key goals are to study how senescent trabecular meshwork (TM) cells in glaucoma patients affect IOP regulation, and to explore whether clearing these senescent cells using senolytic drugs can improve the effectiveness of...
- This $257,785 Project Grant was awarded on April 1, 2025 by the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867). The grant supports the development of a refillable micromachined lens capsule-based drug delivery device for extended intraocular delivery of biologics and immune-modulating peptides to treat non-infectious uveitis. The key products/services to be delivered under this 4-year grant include: Characterizing and controlling the release of the...
- This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides funding to Human Cell Co, a for-profit biotechnology research company, to develop a combination therapy for glaucoma. The award, totaling $360,897, will support research to determine if topical application of a nerve growth factor (NGF) mutein (HC201) in combination with oral nicotinamide (NAM) supplementation can more effectively improve retinal ganglion cell function compared to either treatment...
- The National Eye Institute (NEI), under the U.S. Department of Health and Human Services, awarded a $730,000 Project Grant (CFDA 93.867 - Vision Research) to Human Cell Co, a for-profit biotech firm, to develop an optimized nerve growth factor (NGF) therapy for the treatment of dry eye disease (DED). The funding will support preclinical studies to evaluate the efficacy and mechanism of action of the company's proprietary NGF mutein (HC201) in improving tear film production and corneal...
- This $348,800 Project Grant was awarded on September 30, 2025 by the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), to N'Waii Inc. in Chicago, Illinois. The grant supports the development of a first-in-class mitochondrially targeted antioxidant drug candidate for the treatment of dry eye disease (DED), a condition affecting 20% of the global adult population. The drug candidate exhibits potent free radical scavenging capabilities and has demonstrated...
- This Project Grant award for $679,159 from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), supports research on in vivo epigenetic reprogramming of retinal ganglion cells (RGCs) in aging mice with glaucoma. The research aims to identify new therapeutic targets for glaucoma that can protect and rejuvenate RGCs, which are specifically targeted and damaged in this disease leading to vision loss. The 4-year project, awarded to The Schepens Eye...
- The National Eye Institute (NEI) awarded a $451,000 Project Grant under the Vision Research federal grant program (CFDA 93.867) to The Regents of the University of California, San Francisco (UCSF) to conduct a multimodal characterization of a novel inherited mouse model of glaucoma. The research aims to evaluate structural and functional changes in the mouse model, including axonal degeneration, retinal ganglion cell loss, dendritic changes, and neuroinflammatory responses. It will also identify...
- The National Eye Institute (NEI) awarded a $482,067 Project Grant to Washington State University (WSU) on August 1, 2025 under the Vision Research federal grant program (CFDA 93.867). The grant supports research to develop novel nanotherapies for the targeted treatment of corneal neovascularization, a sight-threatening condition characterized by the growth of blood vessels into the cornea. The funding will enable WSU researchers to synthesize a unique trehalose-based dendrimer (TRE-D) that...
- The National Eye Institute (NEI) awarded a $312,239 Project Grant under the Vision Research federal grant program (CFDA 93.867) to Shift Pharmaceuticals Holdings, Inc. for the development of an antisense oligonucleotide (ASO) therapeutic to inhibit retinoic acid signaling and mitigate vision loss in retinitis pigmentosa and age-related macular degeneration. The project aims to create a targeted ASO therapy that can block the production of retinoic acid receptors at the cellular level within...